Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation

被引:4
|
作者
Gjaerde, Lars Klingen [1 ,2 ,4 ]
Ostrowski, Sisse Rye [2 ,3 ]
Schierbeck, Frederikke [1 ]
Andersen, Niels Smedegaard [1 ]
Friis, Lone Smidstrup [1 ]
Kornblit, Brian [1 ]
Petersen, Soren Lykke
Schjodt, Ida [1 ]
Sengelov, Henrik [1 ,2 ]
机构
[1] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Copenhagen Univ Hosp, Dept Clin Immunol, Rigshosp, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
来源
TRANSPLANTATION AND CELLULAR THERAPY | 2023年 / 29卷 / 02期
基金
新加坡国家研究基金会;
关键词
Allogeneic transplantation; Biomarker; ST2; Nonrelapse mortality; Prognosis; VERSUS-HOST-DISEASE; RISK; GVHD; MODELS; INDEX;
D O I
10.1016/j.jtct.2022.11.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Soluble ST2 is established as a prognostic biomarker of nonrelapse mortality (NRM) when measured early after allogeneic hematopoietic cell transplantation (HCT). However, less is known about the prognostic value of ST2 measured before transplantation. We hypothesized that pretransplantation plasma ST2 level was associated with 1-year NRM and could add to our current prognostic assessment. Moreover, we aimed to investigate the associations between pretransplantation plasma ST2 levels and patient characteristics and other plasma biomarkers and to reproduce previous associations between post-transplantation plasma ST2 levels and outcomes of HCT. We conducted this cohort study of 374 adults who underwent allogeneic HCT at our center between July 2015 and December 2019 (median age, 59 years; 55% with a nonmyeloablative conditioning regimen). ST2 levels were measured by enzyme-linked immunosorbent assay in stored plasma samples obtained at a median of 23 days before HCT and also in samples obtained on days +7 and +14 post-HCT. A logistic regression model of 1-year NRM was fitted using an a priori defined set of covariates consisting of age, Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI), and conditioning intensity (myeloablative versus nonmyeloablative), to which the pretransplantation ST2 level was added as a variable to assess its incremental prognostic value. Models also were fitted of 1-year all-cause mortality, relapse, and grade II-IV acute graft-versus-host disease (GVHD) for pretransplantation and post-transplantation ST2 levels. The median pretransplantation plasma ST2 level was 20.4 ng/mL (interquartile range, 15.2 to 27.2 ng/mL). Pretransplantation ST2 levels were higher in males compared with females (median, 22.2 ng/mL versus 18.1 ng/mL; P < .001) and were correlated with HCT-CI (Spearman ? = .18; P < .001), body mass index (? = .10; P = .05), and plasma levels of C-reactive protein (? = .34; P < .001), creatinine (? = .17; P = .001), and albumin (? = -.17; P < .001). Pretransplantation ST2 levels added prognostic information about 1-year NRM to age, HCT-CI, and conditioning intensity (adjusted odds ratio [OR] of 1-year NRM per 10 ng/mL increase in ST2, 1.32; 95% confidence interval [CI], 1.05 to 1.65; P = .02). Although adding pretransplantation ST2 levels did not notably improve model discrimination (.674 to .675, ?AUC = .001), it increased the diversity of the predicted risks (P = .02, likelihood ratio test). Pretransplantation ST2 levels also were prognostic of 1-year all-cause mortality (adjusted OR per 10-ng/mL increase, 1.23; 95% CI, 1.02 to 1.48; P = .03), but not of relapse (P = .47) or acute GvHD (P = .81). Plasma ST2 levels at day +7 were prognostic of 1-year NRM, all-cause mortality, relapse, and acute GVHD, whereas levels at day +14 were prognostic of 1-year NRM and all-cause mortality. Our results show that pretransplantation plasma ST2 levels added prognostic information about 1-year NRM to age, HCT-CI, and conditioning intensity, and suggest that ST2 has potential as a biomarker of pretransplantation vulnerability and should be considered in future developments of prediction models of NRM after allogeneic HCT.
引用
收藏
页码:97e1 / 97e6
页数:6
相关论文
共 50 条
  • [21] Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study
    Su, Yiqi
    Stern, Anat
    Karantoni, Eleni
    Nawar, Tamara
    Han, Gyuri
    Zavras, Phaedon
    Dumke, Henry
    Cho, Christina
    Tamari, Roni
    Shaffer, Brian
    Giralt, Sergio
    Jakubowski, Ann
    Perales, Miguel-Angel
    Papanicolaou, Genovefa
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (05) : 795 - 804
  • [22] PLASMA ST2 LEVEL BEFORE AND AFTER HEART TRANSPLANTATION
    Gautier, Sergey
    Shevchenko, Alexey
    Mozheiko, Natalia
    Aksenova, Alexandra
    Ulybysheva, Adelya
    Orlov, Vladislav
    Salikhova, Guzel
    Shevchenko, Olga
    TRANSPLANT INTERNATIONAL, 2017, 30 : 224 - 224
  • [23] Hypomagnesemia May Predict Better Survival and Reduced Nonrelapse Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
    Savas, Emine Merve
    Yegin, Zeynep Arzu
    Kok, Munevver Irem
    Karayel, Hande Tugba
    Ozkurt, Zubeyde Nur
    Bozer, Merve Nazl
    Camoglu, Melike
    Gulbahar, Ozlem
    TRANSPLANTATION PROCEEDINGS, 2024, 56 (02) : 386 - 393
  • [24] Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation
    Hotta, Masaaki
    Satake, Atsushi
    Yoshimura, Hideaki
    Fujita, Shinya
    Katayama, Yuta
    Ota, Shuichi
    Hanamoto, Hitoshi
    Oyake, Tatsuo
    Ito, Shigeki
    Okada, Masaya
    Nakanishi, Takahisa
    Ito, Tomoki
    Ishii, Kazuyoshi
    Nomura, Shosaku
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (08): : 660.e1 - 660.e8
  • [25] Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease
    Martinez-Rumayor, Abelardo
    Camargo, Carlos A., Jr.
    Green, Sandy M.
    Baggish, Aaron L.
    O'Donoghue, Michelle
    Januzzi, James L., Jr.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (04) : 578 - 584
  • [26] Amphiregulin, ST2, and REG3 α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
    Etra, Aaron
    El Jurdi, Najla
    Katsivelos, Nikolaos
    Kwon, Deukwoo
    Gergoudis, Stephanie
    Morales, George
    Spyrou, Nikolaos
    Kowalyk, Steven
    Aguayo-Hiraldo, Paibel
    Akahoshi, Yu
    Ayuk, Francis
    Baez, Janna
    Betts, Brian C.
    Chanswangphuwana, Chantiya
    Chen, Yi-Bin
    Choe, Hannah
    Defilipp, Zachariah
    Gleich, Sigrun
    Hexner, Elizabeth
    Hogan, William J.
    Holler, Ernst
    Kitko, Carrie L.
    Kraus, Sabrina
    Al Malki, Monzr
    Macmillan, Margaret
    Pawarode, Attaphol
    Quagliarella, Francesco
    Qayed, Muna
    Reshef, Ran
    Schechter, Tal
    Vasova, Ingrid
    Weisdorf, Daniel
    Woelfl, Matthias
    Young, Rachel
    Nakamura, Ryotaro
    Ferrara, James L. M.
    Levine, John E.
    Holtan, Shernan
    BLOOD ADVANCES, 2024, 8 (12) : 3284 - 3292
  • [27] ST2 and Rg3a As a Biomarker for Predicting of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
    Goker, Hakan
    Aladag, Elifcan
    Buyukasik, Yahya
    Chao, Nelson J.
    Akman, Umit
    Demiroglu, Haluk
    BLOOD, 2019, 134
  • [28] A Comprehensive Model for Predicting 1-Year Survival after Allogeneic Hematopoietic Cell Transplantation in Older Patients
    Gera, Kriti
    Mathavan, Akash
    Mathavan, Akshay
    Tillotson, Sophie G.
    Liu, Xingke
    Guo, Yi
    Farhadfar, Nosha
    Hsu, Jack W.
    Hiemenz, John W.
    Wingard, John R.
    Al-Mansour, Zeina A.
    BLOOD, 2023, 142
  • [29] Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation
    Fu, S.
    Rybicki, L.
    Abounader, D.
    Andresen, S.
    Bolwell, B. J.
    Dean, R.
    Gerds, A.
    Hamilton, B. K.
    Hanna, R.
    Hill, B. T.
    Jagadeesh, D.
    Kalaycio, M. E.
    Liu, H. D.
    Pohlman, B.
    Sobecks, R. M.
    Majhail, N. S.
    BONE MARROW TRANSPLANTATION, 2015, 50 (10) : 1326 - 1330
  • [30] Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation
    S Fu
    L Rybicki
    D Abounader
    S Andresen
    B J Bolwell
    R Dean
    A Gerds
    B K Hamilton
    R Hanna
    B T Hill
    D Jagadeesh
    M E Kalaycio
    H D Liu
    B Pohlman
    R M Sobecks
    N S Majhail
    Bone Marrow Transplantation, 2015, 50 : 1326 - 1330